crh receptor การใช้

• CRH receptor antagonists also have other possible clinical applications aside from the traditional concept of treating depression and anxiety.
• There are four subtypes of the CRH receptor known at present, defined as CRF-1, CRF-2a, CRF-2b, and CRF-2g.
• Studies on mice engineered to have high concentrations of CRH showed higher levels of anxiety, while those engineered to have no or low amounts of CRH receptors were less anxious.
• Reinstatement of conditioned place preference has shown to be blocked when antagonists for CRH receptors are injected into the BNST . Blockage of certain noradrenergic receptors inhibit stress-induced reinstatement.
• It's been hypothesized that patients with clinical conditions that are causally related to HPA hyperactivity, including major depression and post-traumatic stress disorders, may benefit from CRH receptor antagonist treatment.
• Corticotropin-releasing factor binding protein ( CRH-BP ) is thought to play an inhibitory role in which it binds CRH and other CRH-like ligands and prevents the activation of CRH receptors.
• Peptide-based synthetic CRH receptor antagonists have been researched, but as they cannot pass through the blood-brain barrier, clinical research applications seem unlikely at this point, though additional research is still needed.
• CRH receptor antagonists could potentially be used as co-treatments with retinol and flavonoids in order to alleviate the symptoms of chronic inflammatory skin diseases like psoriasis and atopic dermatitis, which are often further exacerbated by HPA actication due to stress.
• There is also hope that CRH receptor antagonists could be useful in the treatment of a range of clinical disorders associated with abnormal stress responses, such as psychosocial growth retardation, euthyroid sick syndrome, stress-induced asthma, and psychogenic impotence.
• Reinstatement of conditioned place preference has shown to be blocked when antagonists for CRH receptors are injected into the BNST . In other words, the effects of stress on reinstatement can be inhibited by blocking the receptor cites for CRH in certain areas of the brain.
• CRH antagonists are believed to work by blocking the consequent secretions of ACTH and cortisol that occur following activation of CRH and lowering the stress-induced rise of CRH in CSF . There is increased clinical interest in CRH receptor antagonists that can cross the blood-brain barrier for the treatment of depression and anxiety, along with other conditions related to HPA hyperactivity, including treatment of irritable bowel syndrome, which is exasperated by stress.